Peter Clark, MD, discusses key updates to NMIBC guidelines, including revisions to risk stratification, the emerging role of biomarkers, and how to navigate treatment options for BCG-unresponsive disease.
Feature|Articles|December 1, 2025
FDA updates in urology: November 2025
Author(s)Hannah Clarke
Fact checked by: Benjamin P. Saylor, Strategic Content Lead
A recap of the FDA submissions and regulatory decisions in urology from November 2025.
Advertisement
Advertisement
Welcome to Urology Times’® monthly FDA update! November was a busy month for regulatory news in urology, with several key approvals and several more agents coming down the pike. This month’s notable advances included the removal of the “black box” warning label on hormone replacement therapy, as well as the approval of pembrolizumab (Keytruda) plus enfortumab vedotin-ejfv (Padcev) for patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based chemotherapy.
Related to this article
Exploratory analyses suggest persistent immune remodeling after aglatimagene plus radiation in localized prostate cancer.
Heather Florio joins to discuss the potential role of supplements in pelvic and sexual health.
John P. Sfakianos, MD, discusses how ctDNA can be optimally integrated into bladder cancer clinical trials.
Robert J. Motzer, MD, discusses the significance of the belzutifan plus lenvatinib approval, adverse event management with the combination, and the evolving role of HIF-2α inhibition in ccRCC.
Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.
The phase 3 BiPASS trial is evaluating the use of 68Ga-PSMA-PET in combination with MRI for pre-biopsy prostate cancer detection.
In RTOG 3506, adding enzalutamide to standard ADT and salvage radiotherapy was associated with 2-year PFS benefit.
Advertisement
Advertisement